Malaria Challenge Study (VAC069)

To register your interest in this trial, please email vaccinetrials@ndm.ox.ac.uk  You will then be emailed a pre-screening questionnaire.

What is the purpose of this trial?

Malaria is a major global health problem. Each year there are more than 200 million cases and over 400,000 deaths each year worldwide. There is a great need for a safe, effective malaria vaccine as the range of malaria medicines is limited and drug resistance is increasing.

Plasmodium vivax (P. vivax) is the second commonest type of malaria parasite. Unlike the most common form, Plasmodium falciparum (P. falciparum), P. vivax is very hard to grow and manipulate in the laboratory so we have a limited understanding of how it infects human red blood cells, how it grows and how the body’s immune system responds to it.

In this study, we are looking for volunteers who will be experimentally infected with malaria on three separate occasions, each time by receiving an injection of a tiny amount of blood containing the P. vivax parasites. This is called a “blood-stage challenge” and will help us develop our understanding of P. vivax malaria, as well as allow us to establish a method that will be used to test out potential future vaccines. Ultimately, in order to test whether a potential new vaccine works, we need to be able to “challenge” vaccinated volunteers with P. vivax malaria infection. We can do this by deliberately infecting volunteers who have been vaccinated, then observing to see if they are protected from malaria infection, or if they develop infection more slowly than volunteers who have not been vaccinated.  

There is considerable experience performing this type of study with the commonest form of malaria, P. falciparum, but within Europe this sort of deliberate infection has not previously been carried out with P. vivax malaria, although the method has been safely conducted in Australia. This study will therefore be important to demonstrate this type of P. vivax challenge is safe, so we can carry out other studies to test vaccines and understand more about the body’s responses to infection in future.

In areas where malaria is common, people are often infected with malaria on multiple occasions and they can develop immune response to malaria over time. In order to study the body’s responses to multiple infections, in this study we will infect volunteers three times. This will allow us to see if there is any difference between the second and third infection, compared to the first.

Condition Studied    Trial Length      Number of Visits

Malaria                     2 years             Maximum of 141

 

Am I eligible to participate?

You must:

  • Be aged 18-50 years old

  • Be in good health

  • If you have previously been in a  vaccine trial that was not for malaria you could still be eligible

You must not:

  • Have had malaria before

  • Have travelled to a malaria endemic region in the last six months, or be intending to travel to one during the time you would be involved in the study

 

FAQ

What does the trial involve?

The three malaria challenges will take place over 2 years. Each malaria challenge has a follow-up period of 3 months, and each challenge will take place approximately 5 months after the last (or 2 months after the previous follow-up). After each malaria challenge, we will follow volunteers closely in clinic until they develop malaria infection, taking blood at each visit. As soon as a volunteer develops malaria infection, treatment will be started. There will be further, less frequent, follow-up appointments until 3 months after each challenge.

Is there any reimbursement for the trial?

Yes, you will be reimbursed at set rates (up to £6000) for your time, inconvenience and travel. Full details of reimbursement can be found in the trial information sheet.

What are the advantages of taking part?

This study will not benefit you, but the information gained from the trial might help to prevent malaria infection and disease in those who live in areas where malaria is common and in travellers. It is hoped that the method tested in this study will allow future studies to assess possible future vaccines against P. vivax, and ultimately contribute to the development of a safe and effective P. vivax malaria vaccine. 

Are there any risks from taking part in the study?

The risks of taking part in this study are very low provided that you return for follow-up as in the information sheet.

What will happen if I don’t want to carry on with the study?

If at any time after agreeing to participate you change your mind about being involved with this study, you are free to withdraw without giving a reason. Your decision will not result in any penalty, or loss of benefits to which you are otherwise entitled. However, if you are enrolled and wish to leave after malaria challenge then you must take the anti-malarial treatment course because of the potentially very serious consequences of untreated malaria infection. Your compensation would be paid as a proportion of the total compensation according to the length of your participation.

For more details about the study, please read the full information sheet by clicking here.

To register your interest in taking part in this study, please email vaccinetrials@ndm.ox.ac.uk  A pre-screening questionnaire will then be emailed to you.